Structure Therapeutics
GPCR
166 hedge funds and large institutions have $2.33B invested in Structure Therapeutics in 2024 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 63 increasing their positions, 33 reducing their positions, and 13 closing their positions.
369% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 13
112% more call options, than puts
Call options by funds: $53.3M | Put options by funds: $25.1M
91% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 33
39% more funds holding
Funds holding: 119 → 166 (+47)
25% more capital invested
Capital invested by funds: $1.86B → $2.33B (+$465M)
3.42% more ownership
Funds ownership: 31.22% → 34.64% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$115M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$70.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$68.8M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$65.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$52.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$37.1M |
| 2 |
HH
HSG Holding
Na,
Hong Kong
|
-$32.8M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$27M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$24.4M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$21.3M |
GPCR Hedge Fund Activity: Q2 2024 in Review
166 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q2 2024, worth a combined $2.33B — up 25% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new GPCR positions and 13 closed out — a net gain of 48 holders — while 63 added to existing stakes and 33 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $115M. The largest seller was TCG Crossover Management, cutting an estimated $37.1M.
- 166 institutional investors held Structure Therapeutics (GPCR) as of Q2 2024, up from 119 in Q1 2024.
- Funds reported $2.33B of Structure Therapeutics stock for Q2 2024, up 25% quarter-over-quarter.
- 61 funds opened new Structure Therapeutics positions in Q2 2024 and 13 closed out, a net change of +48 holders.
- The largest Structure Therapeutics buyer in Q2 2024 was Fidelity Investments, an estimated $115M added.
- The largest Structure Therapeutics seller in Q2 2024 was TCG Crossover Management, an estimated $37.1M sold.
Based on aggregated 13F filings for Q2 2024.